Imperial College London

DrDavidErritzoe

Faculty of MedicineDepartment of Brain Sciences

Academic Clinical Lecturer
 
 
 
//

Contact

 

+44 (0)20 7594 7047d.erritzoe

 
 
//

Location

 

Neuropsychopharmacology UnitBurlington DanesHammersmith Campus

//

Summary

 

Overview

 

  1. Orban C, McGonigle J, Kalk NJ, Erritzoe D, Waldman AD, Nutt DJ, Rabiner EA, Lingford-Hughes AR: Resting state synchrony in anxiety-related circuits of abstinent alcohol-dependent patients. Am J Drug Alcohol Abuse. 2013 Nov;39(6):433-40.
  2. Macoveanu J, Hornboll B, Elliott R, Erritzoe D, Paulson OB, Siebner H, Knudsen GM, Rowe JB. Serotonin 2A Receptors, Citalopram and Tryptophan-Depletion: a Multimodal Imaging Study of their Interactions During Response Inhibition. (Neuropsychopharmacology. 2012 Dec 19. doi: 10.1038/npp.2012.264)
  3. Stokes PR, Benecke A, Myers J, Erritzoe D, Watson BJ, Kalk N, Barros DR, Hammers A, Nutt DJ, Lingford-Hughes AR: History of cigarette smoking is associated with higher limbic GABAA receptor availability. (Neuroimage. 2013 Apr 1;69:70-7. doi: 10.1016/j.neuroimage.2012.12.010. Epub 2012 Dec 14)
  4. Carhart-Harris RL, Leech R, Erritzoe D, Williams TM, Stone JM, Evans J, Sharp DJ, Feilding A, Wise RG, Nutt DJ: Functional Connectivity Measures After Psilocybin Inform a Novel Hypothesis of Early Psychosis. (Schizophr Bull. 2012 Oct 8)
  5. Quelch DR, Parker CA, Nutt DJ, Tyacke RJ, Erritzoe D: Influence of different cellular environments on [(3) H]DASB radioligand binding. (Synapse. 2012 Aug 28)
  6. Licht CL, Christoffersen M, Okholm M, Damgaard L, Fink-Jensen A, Knudsen GM, Erritzoe D: Simultaneous polysubstance use among Danish 3,4-methylenedioxymethamphetamine and hallucinogen users: combination patterns and proposed biological bases. (Hum Psychopharmacol. 2012 Jun 14. doi: 10.1002/hup.2234)
  7. Frokjaer VG, Erritzoe D, Holst KK, Jensen PS, Rasmussen PM, Fisher PM, Baaré W, Madsen KS, Madsen J, Svarer C, Knudsen GM: Prefrontal serotonin transporter availability is positively associated with the cortisol awakening response. (Eur Neuropsychopharmacol. 2012 Jun 23)
  8. Mendez MA, Horder J, Myers J, Coghlan S, Stokes P, Erritzoe D, Howes O, Lingford-Hughes A, Murphy D, Nutt DJ: The brain GABA-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: A pilot [11C]Ro15-4513 positron emission tomography study. (Neuropharmacology, online 21 April 2012, in press)
  9. Colasanti A, Searle GE, Long CJ, Hill SP, Reiley RR, Quelch D, Erritzoe D, Tziortzi AC, Reed LJ, Lingford-Hughes AR, Waldman AD, Schruers KR, Matthews PM, Gunn RN, Nutt DJ, Rabiner EA: Endogenous Opioid Release in the Human Brain Reward System Induced by Acute Amphetamine Administration. (Biol Psychiatry. 2012 Mar 2)
  10. Carhart-Harris RL, Erritzoe D, Williams T, Stone JM, Reed LJ, Colasanti A, Tyacke RJ, Leech R, Malizia AL, Murphy K, Hobden P, Evans J, Feilding A, Wise RG, Nutt DJ: Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. (Proc Natl Acad Sci U S A. 2012 Feb 7;109(6):2138-43. Epub 2012 Jan 23)
  11. Carhart-Harris RL, Leech R, Williams TM, Erritzoe D, Abbasi N, Bargiotas T, Hobden P, Sharp DJ, Evans J, Feilding A, Wise RG, Nutt DJ: Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin. (Br J Psychiatry. 2012 Mar;200(3):238-44. Epub 2012 Jan 26)
  12. Macoveanu J, Hornbøll B, Elliott R, Erritzoe D, Paulson OB, Siebner H, Knudsen GM, Rowe J: Serotonin 2A receptors, citalopram and tryptophan depletion: interactions with response inhibition activity. (Submitted)
  13. Kupers R, Frokjaer VG, Erritzoe D, Naert A, Budtz-Joergensen D, Nielsen FA, Kehlet H, Knudsen GM: Serotonin transporter binding in the hypothalamus correlates negatively with tonic heat pain ratings in healthy subjects: a [11C]DASB PET study. (NeuroImage, 2010, Sept 19).
  14. Erritzoe D, Frokjaer VG, Holst KK, Christoffersen M, Johansen SS, Svarer C, Madsen J, Rasmussen PM, Ramshøy T, Jernigan TL, Knudsen GM: In vivo imaging of cerebral serotonin transporter and 5-HT2A receptor binding in MDMA and hallucinogen users. (Archives of General Psychiatry. 2011, June;68(6):562-76).
  15. Klein AB, Trajkovska V, Erritzoe D, Haugbol S, Madsen J, Baaré W, Aznar S, Knudsen GM: Cerebral 5-HT(2A) receptor and serotonin transporter binding in humans are not affected by the val66met BDNF polymorphism status or blood BDNF levels. (J Cereb Blood Flow Metab. 2010 Aug 25).
  16. Madsen K, Erritzoe D, Mortensen EL, Gade A, Madsen J, Baaré W, Knudsen GM, Hasselbalch S: Cognitive Function is Related to Fronto-striatal Serotonin Transporter Levels - A Brain PET Study in Young Healthy Subjects. (Psychopharmacology, 2010, July 10).
  17.     Svarer C, Thomsen G, Frokjaer VG, Madsen K, Marner L, Erritzoe D, Hasselbalch S, Knudsen GM: An Automatic Method for Semi-Quantitative Assessment of Regional Cerebral Blood Flow Relative to a Database of Healthy Volunteers. (Submitted)
  18.   Frokjaer VG, Erritzoe D, Juul A, Nielsen FAa, Holst K, Svarer C, Madsen J, Paulson O, Knudsen GM: Endogenous plasma estradiol in healthy men is positively correlated with cerebral cortical serotonin 2A receptor binding. (Psychoneuroendocrinology. 2010, 35, 1311—1320).
  19. Rasmussen H, Ebdrup B, Erritzoe D, Aggernaes B, Oranje B, Kalbitzer J, Pinborg L, Baaré WFC, Svarer C, Lublin H, Knudsen GM, Glenthoj B: Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine. (Psychopharmacology, 2010, July 8).
  20. Erritzoe D, Holst KK, Frokjaer VG, Licht CL, Kalbitzer J, Nielsen FAa, Svarer C, Madsen J, Knudsen GM: A non-linear relationship between cerebral serotonin transporter and 5-HT2A receptor binding: An in vivo molecular imaging study in humans. (Jr of Neuroscience, 2010 Mar 3;30(9):3391-7).
  21. Erritzoe D, Frokjaer VG, Haahr MT, Kalbitzer J, Svarer C, Holst KK, Hansen DL, Jernigan T, Lehel S, Knudsen GM: Cerebral Serotonin Transporter Binding is inversely related to Body Mass Index. (NeuroImage, 2010 Aug 1;52(1):284-9. Epub 2010 Apr 9).
  22. Marner L, Gillings N, Madsen K, Erritzoe D, Baaré WFC, Hasselbalch SG, Knudsen GM: Brain Imaging of Serotonin 5-HT4 Receptors in Humans with [11C]SB207145-PET. (NeuroImage, 2010 Apr 15;50(3):855-61. Epub 2010 Jan 22).
  23. Rasmussen H, Erritzoe D, Andersen R, Ebdrup B, Aggernaes B, Oranje B, Kalbitzer J, Madsen J, Pinborg L, Baaré WFC, Svarer C, Lublin H, Knudsen GM, Glenthoj B: Decreased Frontal 5-HT2A Receptor Binding in Antipsychotic-Naïve First-episode Schizophrenia Patients. (Archives of General Psychiatry, 2010 Jan 67(1):9-16).
  24. Kalbitzer J, Erritzoe D, Holst KK, Nielsen F, Marner L, Szabolcs L, Arentzen T, Jernigan TL, Knudsen GM: Seasonal changes in brain serotonin transporter binding in short 5-HTTLPR-allele carriers but not in long-allele homozygote. (Biol Psy, 2010, Jan 26).
  25. Kalbitzer J, Frokjaer VG, Erritzoe D, Svarer C, Cumming P, Nielsen F, Hashemi SH, Baaré WFC, Madsen J, Hasselbalch SG, Kringelbach ML, Mortensen EL, Knudsen GM: The personality trait openness is related to cerebral 5-HTT levels. (NeuroImage, 2009 Apr 1;45(2):280-5).
  26. Frokjaer VG, Vinberg M, Erritzoe D, Svarer C, Baaré WFC, Budtz-Joergensen E, Madsen K, Madsen J, Kessing LV, Knudsen GM: High Familial Risk for Mood Disorder is Associated With Low Dorsolateral Prefrontal Cortex Serotonin Transporter Binding. (NeuroImage, 2009 Jun 46(2):360-6).
  27. Kalbitzer J, Svarer C, Frokjaer VG, Erritzoe D, Baare WFC, Madsen J, Hasselbalch SG, Knudsen GM: A probabilistic approach to delineate functional brain regions. (The Journal of Nuclear Medicine Technology, 2009 Jun 37(2):91-5).
  28. Erritzoe D, Frokjaer VG, Arfan H, Haugbol S, Pinborg L, Svarer C, Madsen J, Paulson OB, Knudsen GM: Serotonin 2A receptor binding in relation to body mass, tobacco and alcohol use. (NeuroImage, 2009, 46:23-30).
  29. Erritzoe D, Rasmussen H, Kristiansen KT, Frokjaer VG, Haugbol S, Baare W, Lublin H, Knudsen GM, Glenthoj BY: Serotonin 2A binding in neuroleptic-naive schizophrenic patients and healthy controls using PET and [18-F]altanserin. (Neuropsychopharmacology, 2008, 33, 2435-2441).
  30. Zhu Z, Guo N, Narendran R, Erritzoe D, Ekelund J, Hwang DR, Bae SA, Laruelle M, Huang Y: The new PET imaging agent [11-C]AFE is a selective serotonin transporter ligand with fast brain uptake kinetics. (Nucl Med Biol., 2004, 31(8):983-994).
  31. 31.    Huang Y, Narendran R, Bae SA, Erritzoe D, Guo N, Zhu Z, Hwang DR, Laruelle M: A PET imaging agent with fast kinetics: synthesis and in vivo evaluation of the serotonin transporter ligand [11-C]2-[2-dimethylaminomethylphenylthio)]-5-fluorophenylamine ([11-C]AFA). (Nucl Med Biol., 2004. 31(6):727-38).
  32. Narendran R, Slifstein M, Talbot PS, Erritzoe D, Huang Y, Cooper T, Martinez D, Kegeles L, Abi-Dargham A, Laruelle M, Hwang D-R: In vivo vulnerability to competition by endogenous dopamine: comparison of the D2 receptor agonist radiotracer (-)-N-[11-C]propyl-norapomorphine ([11-C]NPA) with the D2 receptor antagonist radiotracer [11-C]-raclopride. (Synapse, 2004, 52:188-208).
  33. Erritzoe D, Talbot PS, Frankle WG, Abi-Dargham A: Positron Emission Tomography and Single Photon Emission CT Molecular Imaging in Schizophrenia. (Neuroimaging Clinics of North America, 2003. 13(4):817-832).
  34. Laruelle M, Erritzoe D, Abi-Dargham A, Huang Y: Measurements of Neurotransmitters with Positron Emission Tomography. (Medicine Nucleaire – Imagerie fonctionelle et metabolique, 2003, 9, 41e Colloque Tours).